Research And Development Tenders

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Raltegravir (Atc Code Who: J05aj01)

Open House Biologics Rebate Contracts 2023-04 - Triptorelin Embonat

Completion of Non-exclusive Drug Discounts According to § 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Ranolazine (atc Code Who: C01eb18)

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Raltegravir (atc Code Who: J05aj01)

Conclusion of Non-Exclusive am Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Oh Model for the Active Ingredient Interferon Beta-1A for Subcutaneous Injection (Atc Code According to Who: L03ab07)

Conclusion of Non-Exclusive am Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Oh Model for the Active Substance Mebeverine (Atc Code According to Who: A03aa04)

Completion of Non-exclusive Am Discount Agreements According to Section 130a (8) Sgb V by Means of a So-called Oh Model to the Active Ingredient Mebeverin (atc Code According to Who: A03aa04)

Completion of Non-exclusive Am Discount Agreements According to Section 130a (8) Sgb V by Means of a So-called Oh Model to the Active Ingredient Interferon Beta-1a for Subcutaneous Injection (atc Code According to Who: L03ab07)

Conclusion of Non-Exclusive Discount Agreements According to § 130A Para. 8 Sgb V (Open House Model)

Various Open House Contracts 2023